A Multicenter Randomized Open-label Study of Diammonium Glycyrrhizinate Enteric-coated Capsule Plus DXM Versus DXM in Treatment of ITP

Exclusion Criteria

• •secondary thrombocytopenia;
• •severe immune-deficiency;
• •active or previous malignancy;
• •HIV virus infection, tuberculosis, or other active infection (sepsis, pneumonia, or abscess);
• •pregnancy or lactation;
• •diabetes;
• •hypertension;
• •cardiovascular diseases;
• •severe kidney function impairment;
• •psychosis;
• •osteoporosis;
• •inflammatory bowel disease or gastric disease;
• •arterial or venous thromboembolism within the 6 months before screening or patients who required anticoagulant treatment;
• •an organ or haematopoietic stem-cell transplantation;
• •neutrophil count of less than 1500 cells per mm³;
• •glycosylated haemoglobin less than 8%;
• •partial thromboplastin time 1∙5 times or less the upper limit of normal (ULN); •clinical electrocardiogram changes;
• •history of primary immunodeficiency;
• •neoplastic disease within the past 5 years;
• •corrected QT interval greater than 450 ms for men and greater than 470 ms for women;
• •substance misuse within the previous 12 months;
• •people who could not adhere to the protocol or were planning to have a surgical procedure in 6 months.